ASP Isotopes Inc.

Análisis de la acción ASP Isotopes Inc. (ASPI)

$2.070

-0.191 (-9.21%)Al cierre

Loading chart…
Máximo
2.230
Apertura
2.210
Precio medio ponderado por volumen
2.12
Volumen
5.20M
Capitalización
157.36M
Mínimo
2.050
Importe
11.00M
EV/EBITDA, TTM
-0.97

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets.

aspisotopes.com

Análisis de IA of ASP Isotopes Inc. (ASPI)

Mantener

Given the current price of 2.65 and an RSI of 28.386, ASPI is currently oversold, indicating potential for a rebound. However, the stock has experienced a significant decline of 80.11% over the past year, and the forward P/E ratio is 54.35, suggesting high valuation concerns. The main risk is the negative net income of -33,585,000 reported for Q2 2026, which raises questions about profitability.

Métricas de valoración

El PER previsto actual de ASP Isotopes Inc. (ASPI) es 54.35, frente a su media de 5 años de -2.02.

PER previsto

Sobrevalorado
Media 5A P/E
-2.02
P/E actual
54.35
Sobrevalorada
33.02
Infravalorada
-37.07

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-2.61
EV/EBITDA actual
-0.97
Sobrevalorada
30.93
Infravalorada
-36.14

Precio/ventas previsto

Valor razonable
Media 5A P/S
13.97
P/S actual
5.49
Sobrevalorada
24.31
Infravalorada
3.63

Ballenas con ASPI en cartera

E

Encompass Capital Advisors LLC

+ Con en carteraASPI

-2.29%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-05 (ET)

09:00:00

Latest Data Shows Serve Robotics Borrow Rate Increases to 48.72%

2026-09-29 (ET)

09:00:00

Latest Data Shows Blackstone Borrow Rate Rises to 128.82%

2026-08-20 (ET)

09:30:00

ASP Isotopes Subsidiary Tetra4 Starts Liquid Helium Plant Commissioning

2026-07-21 (ET)

09:30:00

ASP Isotopes Subsidiary Signs Uranium Hexafluoride Research Agreement

2026-07-16 (ET)

17:30:00

ASP Isotopes Files to Sell 23.16M Shares of Common Stock

Noticias

Preguntas frecuentes sobre ASPI, respondidas por Alphio AI

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets. It operates in the Healthcare sector (MISCELLANEOUS CHEMICAL PRODUCTS industry).

Given the current price of 2.65 and an RSI of 28.386, ASPI is currently oversold, indicating potential for a rebound. However, the stock has experienced a significant decline of 80.11% over the past year, and the forward P/E ratio is 54.35, suggesting high valuation concerns. The main risk is the negative net income of -33,585,000 reported for Q2 2026, which raises questions about profitability.

Comunidad

Más ↗
dawn_badger26/9/2026

$ASPI Every year, I tend to have one weak spot in my portfolio. This year, it’s this one. What a disappointment! Monthly chart.

Mostrar más
Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar